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Abstract 
In this work, biodegradable polymers have been successfully used to encapsulate proteins and peptides to prolong 
their therapeutic effect. Biodegradable microspheres prepared using poly(lactic acid), PLA, and its copolymers with 
poly(glycolic acid), PLGA, have been used as protein delivery systems. To overcome common limitation of the 
conventional emulsion/solvent removal techniques SC-CO2 has been proposed as extracting agent of the ‘‘oily’’ 
phase of emulsions, to lead to solvent-free microparticles. Supercritical emulsion extraction, produces an aqueous 
suspension of microparticles after the elimination of the organic solvent contained in the emulsion micelles. The 
process is very fast, due to the enhanced mass transfer of SC-CO2; the fast extraction rate results in a narrower 
particle size distribution (PSD) because droplets aggregation is minimized. The new proposed layout produces micro 
and submicrospheres in a robust and reproducible mode. The continuous process enhances the mass transfer due to a 
large contact area between SC-CO2 and emulsions in the tower, allowing the production of microspheres in short 
processing times and a higher throughput with smaller plant volumes eliminating the batch-to-batch repeatability 
problems. Biopolymer nanoparticles in the range 200-400 nm and microparticles in the range 1-4 µm encapsulating 
bovine serum albumin (BSA) as model protein and insulin like growth factor (h-IGF) were produced. The solvent of 
the oil phase was completely removed operating at 37°C and 100 bar, preventing proteins from degradation.  
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1. Introduction 
Tissue engineering and regenerative medicine hold great promise to restore tissue and organ functions 
with the ambitious goal to avoid organ transplantation. In vitro and in vivo tissue engineering strategies 
generally include signalling molecules, which should try to reproduce the natural sequence of signals 
guiding spontaneous tissue repair. Signalling molecules are mainly growth factors (GFs), a wide variety 
of proteins with distinct properties which are able to act on cell migration, differentiation, proliferation 
and organization in a functional tissue [1]. 
Proteins possess small half-lives and are not capable to diffuse through biological membranes. Their 
instability in the stomach and intestine makes oral delivery of these drugs difficult. Alternative 
administration by frequent injections is also tedious and expensive. Therefore, the development of 
biodegradable polymeric microspheres has been seen as a promising way to overcome the administering 
problems of these macromolecules [2]. A vehicle is needed capable of encapsulating proteins, minimizing 
the mechanisms of degradation and maximizing the in vivo activity, and providing controlled release that 
can be delivered via parental administration is needed. 
Proteins and GFs controlled release from particulate devices has been widely reported in the literature 
[3]. Frequently, these delivery systems were based on natural polymers, such as gelatin and alginate [4,5]. 
Particulate systems based on these polymers are able to encapsulate GFs with minimum loss of 
bioactivity of the encapsulated molecule. However, they lack the capacity to provide long-term release, 
particularly when formed as nanoparticles. These limitations can be overcome by particulate systems 
based on biodegradable polyesters (i.e., PLA, PLGA) [6]. 
However, few sustained release therapeutic protein products based on biodegradable polymers have 
received FDA approval due to the inherent instability of proteins when they are exposed to the conditions 
normally encountered during microparticle fabrication using conventional techniques. Other problems 
encountered are low encapsulation efficiencies and high burst release of the drug. For many therapeutic 
proteins achieving an acceptable dose volume (i.e., high drug content) while maintaining satisfactory 
release kinetics (i.e., minimal burst, acceptable duration) represents a very significant formulation 
challenge [7].  
Different conventional methods have been reported for the preparation of micro and nanoparticles 
including dispersion polymerization [8], nanoprecipitation [9], solvent evaporation of emulsions [10], 
spray drying [11]. These techniques show some drawbacks such as, the use of toxic solvents that have to 
be removed [12,13], and low encapsulation efficiency [14,15]. Conventional solvent evaporation usually 
proceeds at a slow rate and may also require high temperature or reduced pressure to eliminate the 
organic solvent; solvent extraction requires a large amount of external aqueous phase to extract 
completely the solvent [16,17]. Moreover, it is difficult to obtain monodisperse particles using this 
conventional emulsion based technique because, generally, polydisperse microspheres are obtained due to 
the fusion or coagulation of emulsion droplets under mechanically agitation during evaporation [18]. 
A different approach, using a new supercritical fluid technology was recently proposed; SuperCritical-
Carbon Dioxide (SC-CO2) is used as the extracting agent of the oily phase of emulsions to produce 
solvent-free micro or nanoparticles [17,19,20]. Using this new technology named Supercritical Emulsion 
Extraction (SEE) and developed in a continuous layout (SEE-C), the dimension of the biopolymer 
particles are directly related to the dimension of the droplets in the emulsions by a specific shrinking 
factor, related to polymer concentration in the oily phase [21]. The continuous operating layout is 
obtained by means of high-pressure packed tower for emulsion/SC-CO2 contact in counter-current mode, 
allowing a robust and reproducible production [22]. The SEE-C technology has a great potential 
regarding the field of protein encapsulation thanks to the mild extraction condition and the short process 
time.  
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For these reasons, the objectives of this work is to demonstrate that it is possible to apply the SEE-C to 
the production of biopolymeric micro and nanoparticles encapsulating peptides and proteins starting from 
double emulsion. Bovine serum albumin (BSA) has been selected as model protein while insulin like 
growth factor (h-IGF) has been used as peptide. 
2. Materials & Methods 
2.1. Materials 
CO2 (99.9%, SON, Naples, Italy), polyvinyl alcohol (PVA, MW: 30.000–55.000, Aldrich Chemical 
Co.), polysorbate (Tween 80, Aldrich Chemical Co.), poly-lactic acid (PLA, MW: 28.000, Resomer R 
203H, Boehringer), PLGA (PLGA, 75:25 MW: 20000, Resomer RG 752S, Boehringer),  ethyl acetate 
(EA, purity 99.9%, Aldrich Chemical Co.) were used as received. Bovine pancreas albumin (BSA, purity 
99.9%) was obtained by Sigma-Aldrich Co. (Milan, Italy). h-IGF was supplied from PeproTech. 
2.2. Emulsion preparation 
w-o-w emulsions for the encapsulation of BSA (w-o-w ratio: 1:19:80 w/o/w) were prepared using 1mL 
of water/PVA solution (0.04% w/w of PVA), as internal water phase, in which BSA was dispersed at 
0.5% w/w, that was added into polymer/EA solutions (1-10% w/w of PLGA or PLA) and sonicated using 
the Digital Sonifier Branson (mod. 450, ½” diameter micro-tip, 20 kHz). The primary w-o emulsion was, 
then, added into water Tween80 (0.6% w/w Tween80) solution to form the secondary emulsion using a 
high-speed stirrer (mod. L4RT, Silverson Machines Ltd., Waterside, Chesham Bucks, UK). w-o-w 
emulsions for the encapsulation of h-IGF were produced following the same procedure described above, 
adding in the water internal phase the h-IGF at a concentration of 5µg/mL. 
2.3. SEE-C apparatus description 
Detailed description of the SEE-C apparatus is reported in Fig 1. It consisted of a 100 cm long column 
with an internal diameter of about 1 cm. The high pressure column included three stages formed of 
stainless steel cylindrical elements of 30 cm height connected by four way cross- unions and packed with 
stainless steel packing. The apparatus was thermally insulated by ceramic cloths and its temperature 
profile was controlled by six temperature controllers; cross-unions were also used to insert temperature 
controls at different heights of the column. SC-CO2 was fed at the bottom of the column by a high-
pressure diaphragm pump (model Milroyal B; Milton Roy, Pont Saint-Pierre, France) at a constant flow 
rate. The emulsion was taken from a reservoir and fed to the column by a high pressure piston pump 
(model 305; Gilson, Villiers le Bel, France) at the top of the column at a constant flow rate. A separator, 
located downstream the top of the column, was used to recover the extracted oily phase. Particles 
suspension was continuously collected at the bottom of the column by decompression using a needle 
valve. At the end of each run, the suspension was washed several times by centrifugation at 6500 rpm for 
45 minutes with distilled water, recovered by membrane filtration (porosity: 0.1 or 0.4 µm) and 
lyophilized.  
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2.4. Analytical methods 
Field Emission-Scanning Electron Microscope (FE-SEM, mod. LEO 1525; Carl Zeiss SMT AG, 
Oberkochen, Germany) was used to study the morphology of the produced microspheres. A sample of 
powder was dispersed on a carbon tab previously stuck to an aluminum stub. Samples were coated with 
gold (layer thickness 250Å) using a sputter coater (mod.108 A, Agar Scientific, Stansted, UK). Droplet
size distributions (DSD) and particle size distributions (PSD) of microparticles were measured by 
dynamic light scattering (DLS, mod. Mastersizer S, Malvern Instruments Ltd., Worcherstershire, UK). 
PSD and DSD of nanoparticles were measured by DLS using a Malver Zeta Sizer instrument (mod. 
Zetasizer Nano S, Worcestershire, UK).  
Fig. 1. Detailed description of the SEE-C apparatus layout. Vessel CO2 (CO2); Cooler (C); Pump_CO2 (P_CO2); heater (H); 
Pump_Emulsion (P_E); on-off valves (V); micrometering valve, (V-3); Manometer (PC); Flow measurement (FC); Separator (SEP). 
Extraction pressure and temperature conditions fixed at 80 bar and 38°C were used to process 
emulsions with an oily phase content of about 20% w/w. They were selected to assure the complete 
miscibility of EA in SC-CO2 [21]; a temperature of 38°C is also compatible with protein processing. The 
counter-current operation in the packed column is also favored by large density differences between the 
two phases involved in the process. Using supercritical fluid, the lower is the pressure the larger is the 
density difference between a liquid and SC-CO2 at fixed temperature. Therefore, fixing the temperature at 
38°C and operating at 80 bar, the maximum difference in density between the emulsion and SC-CO2 is 
obtained because they are of 1 g/cm3 against 0.3 g/cm3, respectively. Finally, the ratio between the 
emulsion and SC-CO2 (liquid/gas ratio, L/G) was fixed at 0.1 according to previous optimization [21], to 
obtain the minimum solvent residue in the final suspension. 
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3. Results and discussion 
3.1. BSA encapsulation study 
Micro and nanoparticles of PLGA and PLA loaded with BSA were produced using a double emulsion 
w/o/w (1/19/80) with a water internal phase charged with BSA (2.5-5 mg/mL) and PVA (0.04% w/w). 
In the case of microparticle production, the oily dispersed phase was formed by a polymer solution in 
ethyl acetate at 10% w/w. The water external phase was formed by water saturated with ethylacetate plus 
Tween80 as surfactant (0.6% w/w). The primary emulsion w/o was obtained by ultrasonication. Then the 
primary emulsion was added to the external water by a rotative system at 3300 rpm for 6 minutes. Optical 
images of emulsions obtained using PLGA and PLA and at different BSA loading are reported in the 
figures 2 a-c. FESEM images of the microparticles obtained after SEE-C process are also reported in 
figures 2d-f. 
Fig. 2. a-f. Optical microscope images of different emulsion obtained for microparticles production. Two different polymer PLGA 
and PLA are used at two different BSA loading. FESEM images of the microsphere produced after SEE-C are also reported.
Images in Fig. 2. show that stable emulsions were formed in each case with well defined droplets. 
Polymer precipitation inside the droplets was induced by SC-CO2 extraction of the organic solvent of the 
oily dispersed phase and microparticles suspension was obtained with a yield higher than 90%. Particles 
were always spherical and non coalescing. A medium shrinkage factor of 4% between droplet mean size 
of the emulsion and particles mean size was observed. In particular PLGA gives particles with MS =2.6 
and SD=0.56 µm, while PLA, at the same process conditions, gives particles with MS =1.98 and SD=0.28 
µm. BSA was encapsulated with two different loading 2.5 mg/gr and 5 mg/gr of PLGA and no 
considerable variation in the PSD of the microsphere obtained was observed with respect of the two 
different loading tested. 
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In the case of nanoparticle production, the oily phase was formed by a polymer solution in ethyl 
acetate at 1% w/w. The primary w/o emulsion was obtained again by ultrasonication. Then, it was added 
to the external water phase by a rotative system operating at 6000 rpm for 6 minutes. At the end the final 
emulsion was sonicated again at 30% amplitude for 2 minutes. Examples of FE-SEM images of 
nanoparticles of PLGA and PLA with BSA loading of 5 mg/gr of polymer obtained after SEE-C 
processing are reported in Fig. 3.a-c, respectively. DSD of the emulsions and PSD of the suspensions 
were also reported for comparison in Figures 3b-d. 
Nanoparticles with a mean diameter of about 300 nm were produced in both cases after SEE process, 
PLA gives more uniform PSD with a smaller SD. A medium shrinkage factor of 15% between droplet 
mean size of the emulsion and particles mean size of the suspension of nanoparticles was observed.  
Fig. 3. a d. FESEM images of the nanosphere produced after SEE-C process are also reported. DSD and PSD are also reported. 
3.2. h-IGFs encapsulation 
Microparticles of PLGA loaded with h-IGF were produced using the same emulsion described in the 
case of BSA encapsulation in PLGA microparticles; a double emulsion w/o/w (1/19/80) was used in 
which in the internal water phase at the aqueous solution of BSA (2.5 mg/mL) was added 5 ug/mL of h-
IGF and PVA (0.04% w/w). BSA also acts as stabilizing and protecting agent for the growth factor. The 
oil phase was composed of a polymeric solution in ethyl acetate at 10% w/w of PLGA. The water external 
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phase was formed by water saturated with ethylacetate plus Tween80 as surfactant (0.6% w/w). The 
primary emulsion w/o was obtained again by ultrasonication. Then the primary emulsion was added to the 
external water phase and the emulsion was obtained agitating the system at 3300 rpm for 6 minutes. 
An optical image of the produced emulsions and a SEM image of the derived devices are reported in 
Fig. 4a-b. Again produced PLGA microparticles were spherical and non coalescing. Microparticles with a 
mean size of 2.5 µm (SD=0.3) µm were obtained. The PSD was the same of the one obtained using the 
same system but charged only with BSA and described before, confirming the high reproducibility of the 
SEE-C process. Loading measurement and release profiles are in progress. 
Fig. 4. a-b. Optical microscope images of emulsion obtained for the production of PLGA microparticles encapsulating h-IGF. FE-
SEM images of the microsphere produced after SEE-C process are also reported.  
4. Conclusions  
SEE was successfully applied for the production of micro and nanospheres of PLGA and PLA 
encapsulating a protein and a peptide. Different emulsion formulation and preparation methods were 
applied tuning particles dimensions form 2.5 µm to 300 nm for both polymer tested. The same emulsion 
formulation used to produce microparticles of PLGA was used to encapsulate h-IGF. Emulsions produced 
were always stable and non coalescing. Precipitation of PLGA or PLA inside the droplets is induced by 
SC-CO2 extraction of the organic solvent of the oily dispersed phase using a continuous counter-current 
tower. Thanks to the peculiar properties of the SC-CO2, opportunely chosen the operative conditions of 
the SEE-C process in terms of pressure, temperature and liquid and gas flow rate, a very efficient and fast 
extraction of the oily solvent of the emulsion is obtained, producing the hardening of the polymer and the 
entrapment of the protein/peptide inside the particles. PSD very close to DSD were obtained 
demonstrating the absence of aggregation phenomena during the SEE-C process. 
Further study of characterization of the SEE-C products obtained and illustrated in this work are in 
progress. In particular protein and peptides loading and release are under study, as well as investigation 
about the possible degradation of the proteins/peptides during the SEE-C process.  
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